Covidien Unveils The Next Generation In Advanced Surgery

Main Category: Medical Devices / Diagnostics
Also Included In: GastroIntestinal / Gastroenterology
Article Date: 14 Apr 2008 - 1:00 PDT

email to a friend   printer friendly   opinions  

Covidien (NYSE: COV, BSX: COV), a leading global provider of healthcare products, announced that its Energy-based Devices business unit has introduced LigaSure Advance™, the first multifunctional laparoscopic instrument that offers surgeons fingertip control of both tissue fusion and monopolar dissection.

LigaSure Advance™ was created in response to what surgeons said they need to optimize efficiency and safety in the operating room. This latest innovation in the LigaSure™ lineup is a 5 mm hand-activated instrument that provides surgeons with the ability to create fusion cycles in two to four seconds, and when used with Valleylab™ mode, the unique energy modality delivers dissection and hemostasis.

With sterile-field control of mode and power settings, LigaSure Advance™ is designed to enable surgeons and perioperative staff to focus more effectively on the procedure and patient. Its versatility reduces the need for instrument exchanges, making procedures more efficient and potentially reducing overall operating time.

"My initial impression when I used the LigaSure Advance™ in laparoscopic colon surgery centered on versatility," said Morris E. Franklin Jr., M.D., Texas Endosurgery Institute, San Antonio, Texas. "Having both LigaSure™ and monopolar capabilities in one instrument significantly reduces surgical time, as less time is lost changing between instruments."

LigaSure Advance™ is for use exclusively with the ForceTriad™ energy platform controlled by TissueFect™ sensing technology, which in one unit supplies the operating room with enhanced monopolar, bipolar and tissue fusion energy.

"We found the LigaSure Advance™ to be far faster and more effective than conventional clamp and tie methods," said Todd Heniford, M.D., Carolinas Medical Center, Charlotte, N.C. "For bowel mesentery resections, the added benefit of an incorporated dissecting electrode may lead to reduced operative time and less hand fatigue."

"We are excited to introduce this innovative surgical instrument to the marketplace. We are confident it better serves the needs of our customers and further advances patient care," said Bryan Hanson, President, Energy-based Devices, Covidien. "The launch of the LigaSure Advance™ instrument once again reflects Covidien's continuing commitment to be a leading provider of first-in-class electrosurgical devices."

About Covidien

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2007 revenue of nearly $9 billion, Covidien has more than 43,000 employees worldwide in 57 countries, and its products are sold in over 130 countries.

Covidien

• Additional
• References
• Citations